GlassScriptPhysician profile
Michele Owaski
NPI 1104277797
$3,908.46
in general payments reported to CMS, 2019-2025
30 companies · $742 in 2025
The $742 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,399 · 2022: $495 · 2023: $691 · 2024: $582 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,273.11 | 2021-2024 | |
| Amgen INC. | $349.00 | 2021-2023 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.98 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $187.70 | 2022-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $173.78 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.66 | 2021-2022 | |
| Genzyme Corporation | $147.49 | 2021 | |
| Lnhc, INC | $136.36 | 2025 | Zelsuvmi |
| Ucb, INC. | $136.00 | 2023-2025 | Bimzelx |
| Organon LLC | $133.86 | 2025 | Vtama |
| Almirall LLC | $128.16 | 2021 | |
| Janssen Biotech, INC. | $124.99 | 2023 | Tremfya |
| Arcutis Biotherapeutics, INC. | $106.57 | 2023-2025 | Zoryve |
| Kerecis Limited | $94.13 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Incyte Corporation | $55.75 | 2022-2025 | Opzelura |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $53.29 | 2021 | |
| Lilly USA, LLC | $49.47 | 2021-2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $44.93 | 2021-2024 | |
| Organogenesis INC. | $41.93 | 2021-2022 | |
| Leo Pharma INC. | $41.26 | 2021-2025 | Spevigo |
| Biocon Biologics INC | $40.53 | 2025 | Yesintek |
| Regeneron Healthcare Solutions, INC. | $40.05 | 2021-2023 | Dupixent |
| Fresenius Kabi USA, LLC | $33.91 | 2023 | |
| Boston Scientific Corporation | $30.42 | 2023 | |
| Biofrontera INC. | $28.39 | 2021-2025 | Ameluz |
| Mayne Pharma Commercial LLC | $21.06 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.53 | 2023 | |
| Botanix Sb INC | $18.56 | 2025 | Sofdra |
| Pfizer INC. | $13.80 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Owaski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.